Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on long-term clinical data

Journal of Managed Care Pharmacy

Volumn 13, Issue 3, 2007, Pages 245-261

  Bell, Christopher ^a   Graham, Jonathan ^a   Earnshaw, Stephanie ^a   Oleen Burkey, Merrikay ^b   Castelli Haley, Jane ^b   Johnson, Kenneth ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b Teva Neuroscience Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Immunodulatory therapy; Markov model; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

ABSENTEEISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FOLLOW UP; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; META ANALYSIS; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PATIENT CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SENSITIVITY ANALYSIS; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 34248380578     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.3.245     Document Type: Article

References (99)

1. National Multiple Sclerosis Society. National MS Society Information Sourcebook. 2005. Available at: http://nationalmssociety.org/ sourcebook.asp. Accessed November 1, 2005.
2. Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology. 2003;61(10):1373-77.
3. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58(1):136-38.
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989;112(pt 6):1419-28.
5. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980;103(2):281-300.
6. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology. 2002;59(6 suppl 3):S1-S33.
7. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-11.
8. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(pt 10):1941-50.
9. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess. 2002;6(10):1-73.
10. Rice GPA, Kremenchutzky M, Cottrell DA, Baskerville J, Ebers GC. Observations from the natural history cohort of London, Ontario. In: Filippi M, Comi G, eds. Topics in Neuroscience: Primary Progressive Multiple Sclerosis. Milano: Springer Verlag Italia; 2002.
11. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989,112(pt 1):133-46.
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-76.
13. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-94.
14. Clanet M, Radue EW, Kappos L, et al. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology. 2002,59(10):1507-17.
15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
16. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655-61.
17. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662-67.
18. Durelli L, Verdun E, Barbero P et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002; 359(9316):1453-60.
19. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59(10):1496-1506.
20. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50(3):701-08.
21. Clanet M, Kappos L, Hartung HP, Hohlfeld R. interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. Mult Scler. 2004; 10(2):139-44.
22. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56(12):1628-36.
23. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-85.
24. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6(4)255-66.
25. Johnson KP, Ford CC, Lisak RP, Wolinsky JS. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand. 2005,111(1):42-47.
26. Kappos L, Stam Moraga M, Alsop JC. Long-term tolerability of interferon beta-1a in relapsing-remitting multiple sclerosis: 6-year safety follow-up of the PRISMS study [abstract P334]. Presented at: Joint Meeting of the Americas and European Committees for Treatment and Research in Multiple Sclerosis; September 18-22, 2002; Baltimore, MD.
27. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-53.
28. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006;12:309-20.
29. National Institute for Clinical Excellence. Beta Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis. Technology Appraisal Guidance No. 32. London: National Institute for Clinical Excellence; 2002.
30. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ. 2003;326(7388):522.
31. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78.
32. First Data Bank. Data on file. Teva Neuroscience; 2006.
33. Drug Topics Red Book for Windows. Version 61127. Vol. 36. Montvale, NJ: Thomson PDR 2006; April 2005 release date.
34. Lundy J, Craig BM. The use of disease-modifying agents among multiple sclerosis patients enrolled in Medicare from 1995 to 2002 and the impact of Medicare Part D: analysis of claims data from the Medicare current beneficiary survey. Clin Ther. 2006;28(1):140-45.
35. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler. 1998;4(5):419-25.
36. Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232-39.
37. Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91-98.
38. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17.
39. Orlewska E, Mierzejewski P, Zaborski J, et al. A prospective study of the financial costs of multiple sclerosis at different stages of the disease. Eur J Neurol. 2005;12(1):31-39.
40. Kobelt G, Jonsson L, Fredrikson S. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ. 2003; 4(1):50-59.
41. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health. 2002;5(1):44-54.
42. Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. Mult Scler. 2005;11(5):542-51.
43. Bose U, Ladkani D, Burrell A, et al. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis: first estimates. J Med Econ. 2001;14:207-19.
44. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess. 1998; 2(4):iii-54.
45. Phillips CJ, Gilmour L, Gale R, et al. A cost utility model of beta-interferon in the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2001;4:35-50.
46. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health. 2004;7(5):554-68.
47. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-42.
48. Rossman HS. Neutralizing antibodies to multiple sclerosis treatments. J Manag Care Pharm. 2004;10(3)(suppl):S12-S19. Available at: http:// www.amcp.org/data/jmcp/june04Supplement1.pdf. Accessed March 5, 2007.
49. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52.
50. Gold M, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
51. Oleen-Burkey M, Kobelt G, Borgstrom F. Costs and quality of life of patients with relapsing-remitting multiple sclerosis currently on immunomodulatory therapy in the United States [abstract]. International Committee on Databases in Multiple Sclerosis, 2003.
52. Kobelt G. Economic evidence in multiple sclerosis: a review. Eur J Health Econ. 2004;(5 suppl 1):S54-S62.
53. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the United Kingdom. Stockholm: Stockholm School of Economics; 2000. EFI Research Report No. 398.
54. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006,66(11):1696-1702.
55. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L. Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology. 1994;44(1):28-33.
56. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology. 2004; 62(1):51-59.
57. MacLurg K, Reilly P, Hawkins S, Gray O, Evason E, Whittington D. A primary care-based needs assessment of people with multiple sclerosis. Br J Gen Pract. 2005;55(514):378-83.
58. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol. 1989;46(10):1107-12.
59. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci. 1987;14(3):255-61.
60. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116 (pt 1): 117-34.
61. Centers for Disease Control and Prevention. U.S. vital statistics reports. Table 3. Number of deaths and death rate, by age, race, and sex. 2003;52(3). Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr52/ nvsr52_03.pdf. Accessed June 17, 2005.
62. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in northeast Scotland. J Neurol Neurosurg Psychiatry. 1987;50(5):523-31.
63. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol. 1998;43(1):79-87.
64. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545-52.
65. Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2001;(4):CD002002.
66. Khan O, Zabad R, Caon C, Zvartau-Hind M, Tselis A, Lisak R. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(8):563-78.
67. Kappos L, Clanet M, Sandberg-Wollheim M, et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology. 2005; 65(1):40-47.
68. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology. 2005;65(1): 48-55.
69. Giovannoni G, Munschauer FE III, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;73(5):465-69.
70. Medical Consumer Price Index. Gabriel, Roeder, Smith & Company Available at: www.grsnet.con/grs_library/index.html. Accessed June 17, 2005.
71. Frohman EM, Stuve O, Havrdova E, et al. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol. 2005;62(10):1519-30.
72. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-54.
73. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-09.
74. Lichtenberg FR. Availability of new drugs and Americans' ability to work. J Occup Environ Med. 2005;47(4):373-80.
75. Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work. 2006;27(2):143-51.
76. Busche KD, Fisk JD, Murray TJ, Metz LM. Short term predictors of unemployment in multiple sclerosis patients. Can J Neurol Sci. 2003;30(2):137-42.
77. Kobelt G. Costs and quality of life in multiple sclerosis: a cross-sectional study in the USA. Stockholm: Stockholm School of Economics; 2004. EFI Working Paper Series in Economics and Finance No. 594.
78. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess. 1998; 2(4):iii-54.
79. Academy of Managed Care Pharmacy. AMCP Format for Fomulary Submissions, version 2.1. 2005. Available at: http://www.fmcpnet.org/ data/resource/Format~Version_2_1_Final-Final.pdf. Accessed January 2, 2007.
80. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCHOTA); 1997.
81. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Clinical Excellence (NICE); 2004.
82. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler. 2003;9(3):311-19.
83. Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatmetn. CNS Drugs. 2004;18(9):561-74.
84. Maetzel A, Krahn M, Naglie G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum. 2003;49(3):283-92.
85. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26(9):2518-23.
86. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment Pharmacol Ther. 2003;17(8):1021-30.
87. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Marms BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64(1):295-304.
88. Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am J Prev Med. 2000,19(1):15-23.
89. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther. 2003;25(9):2464-86.
90. Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs. 2002;16(12):825-50.
91. McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs. 2004;18(8):521-46.
92. Association of British Neurologists. Guidelines for the use of beta interferons and glatiramer acetate in multiple sclerosis; 2001. Accessed January 2, 2007.
93. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11(1):46-50.
94. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler. 2005;11(6):626-34.
95. Ebers G, Rice G, Wolf C, et al. 16-year long-term follow-up of interferon beta-1b treatment in RRMS. Neurology. 2005,64(suppl 1):A385.
96. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139): 1491-97.
97. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology. 2001; 56(11):1496-1504.
98. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898-904.
99. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59(5): 679-87.